Anwaar Saeed, MD
Medical Oncology · Westwood, KSNPI 1447490974
Payments from drug & device makers
Across 435 payments — averaging $9453.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.5M
- AstraZeneca$843K
- Exelixis Inc.$739K
- Seagen Inc.$231K
- Alnylam Pharmaceuticals Inc.$142K
- Beone Medicines Ltd.$100K
- plus $512K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 129 | $1,545,377 |
| AstraZeneca | 40 | $842,889 |
| Exelixis Inc. | 121 | $738,578 |
| Seagen Inc. | 36 | $230,843 |
| Alnylam Pharmaceuticals Inc. | 9 | $142,097 |
| Beone Medicines Ltd. | 1 | $100,332 |
| E.r. Squibb & Sons, L.L.C. | 11 | $99,948 |
| Coherus Oncology, Inc. | 4 | $88,280 |
| Daiichi Sankyo Inc. | 21 | $84,412 |
| Beone Medicines USA, Inc. | 9 | $62,515 |
| Pfizer | 2 | $42,717 |
| Biontech SE | 11 | $41,434 |
| Incyte Corporation | 1 | $19,190 |
| Astrazeneca UK Limited | 1 | $19,055 |
| Boehringer Ingelheim | 1 | $17,830 |
| Amgen | 6 | $12,434 |
| GSK | 5 | $5,466 |
| Genentech, Inc. | 2 | $4,940 |
| Regeneron | 11 | $4,752 |
| Array Biopharma Inc | 4 | $3,780 |
| Jazz Pharmaceuticals Inc. | 2 | $2,898 |
| Taiho Oncology, Inc. | 1 | $2,310 |
| Astellas Pharma US Inc | 1 | $124 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $93 |
| Gilead | 2 | $74 |
| Eisai Inc. | 1 | $50 |
| Ipsen Biopharmaceuticals, Inc | 2 | $30 |
How this compares
$4,112,447 in reported general payments places this provider in the 90th percentile of 25 medical oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Westwood
- Weijing SunWestwood$5.1M
- Rahul ParikhWestwood$4.5M
- Joaquina BarandaWestwood$2.7M
- Anne OdeaWestwood$2.2M
- Stephen WilliamsonWestwood$861K
- Elizabeth WulffWestwood$529K
- Saqib AbbasiWestwood$108K
- Sarah TaylorWestwood$56K
- Ajjai AlvaOverland Park$3.7M
- Nisreen HaideriOverland Park$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.